Recent studies underscore the lackluster performance of cancer diagnostics, including measurement of prostate specific antigen (PSA) in prostate cancer. PSA levels measured routinely as a minimally invasive blood test may inaccurately reflect disease. To advance our capacity to identify & treat prostate cancer, new indicators of disease state, therapeutic response and outlook are needed. Prostate circulating tumor cells (CTCs) offer potentially powerful new biomarkers for understanding cancer. The impetus for single-CTC analysis stems from the observed cellular heterogeneity in solid tumor microenvironments. CTCs are believed to initiate metastasis, accounting for approximately 90% of deaths from solid tumors. Previous studies link CTC enumeration to patient outcome. CTC analysis may provide insight into therapies. While molecular analyses of single-cells has advanced tremendously over the last decade, revealing genetic diversity in tumor cell subpopulations, a complete understanding of cancer progression and variability requires tools to assess protein-mediated signaling directly. A major limitation on querying CTCs for protein- level information stems from the staggeringly low number of CTCs found in blood (i.e., 1 CTC per billion normal blood cells). Out of necessity, protein assays are performed on CTC populations, ignoring the inherent variability between cells. Yet, we know that cell-to-cell variability may hold information crucial to understanding the initiation and final stages of metastasis, as well as in identifying promising drug targets and candidates for stemming metastasis. In conjunction with our clinical collaborators at Stanford, we will significantly advance and expand on our recently introduced single-cell microfluidic Western blot array to quantify protein expression in single CTCs collected via MagSweeper from prostate cancer patients. Our work will enable first-in-kind Western blotting of single CTCs. To do this, we will: (1) introduce a single-cell scWestern array optimized for low starting numbers of CTCs (10-100 cells), in tandem with introducing high sensitivity readouts, (2) apply single CTC Western blotting to analyses of differential expression of targeted proteins in a suite of cell types with increasing degree of hypothesized metastatic potential, and (3) introduce fluid flow control to the single-CTC Western array for in situ cell surface antigen staining to allow correlation with intracellular protein-mediated signaling. Taken together, our work will advance cancer research by allowing for inclusion of CTC-level protein data. Looking forward, the new knowledge gained as a result of our IMAT success would notably advance clinical practice by enabling study of promising CTC biomarkers of sensitivity/acquired resistance to novel cancer therapies and in identifying potential therapeutic targets to halt cancer metastasis. Protein-level characterization of CTCs is important to realizing truly personalized medicine.

Public Health Relevance

Cancer exhibits tremendous molecular level heterogeneity, also thought to exist in circulating tumor cells. New technologies for measuring this diversity in circulating tumor cells have been focused on genomic information. Yet, proteins play a critical role in cancer metastasis initiation. This project introduces new tools for measuring the variability of protein expression, modification, and complexing arising in intracellular signaling o enable finely tuned, personalized therapy relevant to cancer metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA183679-03
Application #
9294994
Study Section
Special Emphasis Panel (ZCA1-SRLB-Q (O1))
Program Officer
Mckee, Tawnya C
Project Start
2015-06-09
Project End
2018-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
3
Fiscal Year
2017
Total Cost
$181,878
Indirect Cost
$41,169
Name
University of California Berkeley
Department
Biomedical Engineering
Type
Schools of Engineering
DUNS #
124726725
City
Berkeley
State
CA
Country
United States
Zip Code
94704
Kang, Chi-Chih; Ward, Toby M; Bockhorn, Jessica et al. (2018) Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution. NPJ Precis Oncol 2:10
Abdel-Sayed, Philippe; Yamauchi, Kevin A; Gerver, Rachel E et al. (2017) Fabrication of an Open Microfluidic Device for Immunoblotting. Anal Chem 89:9643-9648
Neira, Hector D; Herr, Amy E (2017) Kinetic Analysis of Enzymes Immobilized in Porous Film Arrays. Anal Chem 89:10311-10320
Sinkala, Elly; Sollier-Christen, Elodie; Renier, Corinne et al. (2017) Profiling protein expression in circulating tumour cells using microfluidic western blotting. Nat Commun 8:14622
Su, Elaine J; Herr, Amy E (2017) Electrophoretic cytometry of adherent cells. Lab Chip 17:4312-4323
Duncombe, Todd A; Kang, Chi-Chih; Maity, Santanu et al. (2016) Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting. Adv Mater 28:327-334
Kang, Chi-Chih; Yamauchi, Kevin A; Vlassakis, Julea et al. (2016) Single cell-resolution western blotting. Nat Protoc 11:1508-30
Kang, Chi-Chih; Lin, Jung-Ming G; Xu, Zhuchen et al. (2014) Single-cell Western blotting after whole-cell imaging to assess cancer chemotherapeutic response. Anal Chem 86:10429-36